Zinc increases phorbol ester receptors in intact B-cells, neutrophil polymorphs and platelets  by Forbes, I.J. et al.
Volume 241, number 2, 445-447 FEB 07065 April 1989 
Zinc increases phorbol ester receptors in intact B-cells, neutrophil 
polymorphs and platelets 
I.J. Forbes, P.D. Zalewski, N.P. Hurst*, C. Giannakis and M.W. Whitehouse 
Department of Medicine, University of Adelaide, *Rheumatology Unit, Queen Elizabeth Hospital, Woodville, SA 5081 and 
Department of Pathology, University of Adelaide, Adelaide, Australia 
Received 3 March 1989 
In the presence of pyrithione, which was used as a Zn *+ ionophore, Znzf (l&l00 PM) increased phorbol ester binding 
by intact B-CLL cells in a dose-dependent fashion. Zn pyrithione increased 2-fold the number of phorbol ester receptors 
in B-cells (0.74 to 1.4 pmol/lV cells), neutrophil polymorphs (0.2 to 0.51 pmol/lW cells) and platelets (91 to 209 pmol/lOiO 
cells). Fractionation of cells after treatment with Zn pyrithione showed that increased binding of PDBu occurred in the 
particulate fraction of cells and this was accompanied by loss of phorbol ester receptors from the cytosol. These data 
are compatible with a role for Zn in the subcellular distribution and activation of protein kinase C. 
Zinc; Protein kinase C; (B-cell, Neutrophil, Platelet) 
1. INTRODUCTION 
The Ca’+/phospholipid-dependent protein ki- 
nase, protein kinase C (PKC), is now known to 
represent a family of isoenzymes which are ac- 
tivated by 1,2-diacylglycerol or phorbol esters [I]. 
Sequence studies indicate a conserved cysteine-rich 
region [2] in the regulatory domain of PKC; the lat- 
ter also contains the binding site for 1,2-diacyl- 
glycerol or phorbol esters. As this cysteine-rich 
region is homologous with the ‘zinc fingers’ found 
in some DNA-binding proteins, it may permit PKC 
to bind specific DNA sequences [2]. The relation of 
the cysteine-rich region to the phorbol ester- 
binding site is not known. Recent reports have in- 
dicated that Zn2+ modulates the catalytic activity 
of PKC [3] and alters the affinity of phorbol ester 
receptors in cytosol of T-cells [4]. In these ex- 
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periments we have examined the effect of increases 
in intracellular Zn” on phorbol ester binding in in- 
tact B-CLL cells, neutrophil polymorphs and 
platelets using pyrithione as a Zn2+ ionophore. 
2. MATERIALS AND METHODS 
“ZnCla (spec. act. 1.667 Ci/g; Amersham Australia Pty); (4.4 
mM) was diluted to 1 mM with distilled water. This was mixed 
1:2O with unlabelled ZnC12 (1 mM) to provide a 1 mM stock 
solution. B-CLL cells were obtained from patients with CLL 
who were undergoing leukapheresis, washed and stored in liquid 
Na until ready for use. After removal of contaminating 
erythrocytes and neutrophils by FicolVHypaque centrifugation, 
B-CLL cells were washed twice and resuspended in phosphate- 
buffered saline (PBS) (PH 7.4). Platelets were obtained from 
platelet-rich plasma, centrifuged, washed and resuspended in 
buffer as for CLL cells. PDBu-binding assays on cytosol were 
performed in buffer containing 4 mM MgCla, 5 mM CaCls, 1 
mg/ml BSA, 25 mM Hepes, 25 mM Tris-HCl (pH 7.5). B-CLL 
cells or platelets were incubated with [3H]PDBu with or without 
Zn2+ and/or pyrithione for 30 min prior to assay of [‘H]PDBu- 
binding (in triplicate) as described [5]; non-specific binding was 
assayed in the presence of a 50-fold molar excess of unlabelled 
phorbol ester. To prepare subcellular fractions, B-cells were 
suspended in Tris-HCl (pH 7.5) containing 0.1 m&ml leupeptin 
and 1 mM EDTA and sonicated (six 5-s bursts). The sonicate 
was then centrifuged to provide a post 30000 x g supernatant 
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(soluble fraction) and pellet (particulate fraction). To measure 
65Zn uptake, cells (lo7 in 40~1) were incubated with 10 or 100 
PM 65Zn (40 ~1 stock 1 mM solution), pyrithione (20 ~1 of re- 
quired concentration) and buffer (300~1) (as for PDBu-binding 
assay). Control cells were incubated without pyrithione. After 
30 min, cells were washed once at 4°C with PBS containing 1 
mM phenanthroline to chelate extracellular Zn, then 3 times 
with PBS containing 100 PM unlabelled Zn2+ in place of 
phenanthroline. The 65Zn content of cell pellets was measured 
using an LKB y-counter; cellular uptake of 65Zn was calculated 
by subtracting counts measured in cells incubated without 
pyrithione from those incubated with pyrithione. 
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3. RESULTS AND DISCUSSION 
Zn’+ (O-100,uM) in the presence of pyrithione in- 
creased specific binding of [‘H]PDBu to B-CLL 
cells in a concentration-dependent manner 
(fig.lA). Pyrithione in the absence of added Zn2+ 
also stimulated a small increase in binding of 
[‘H]PDBu; this effect is probably due to the 
presence of Zn’+ (~2 PM) in the incubation 
medium. The time course of the increase in 
[3H]PDBu binding was closely paralleled by in- 
creases in cellular Zn content (fig.lB). The Zn2+ 
chelator phenanthroline caused slight inhibition of 
PDBu binding in control preparations, completely 
inhibited the enhancing effect of Zn2+ and 
pyrithione on PDBu binding when added shortly 
after Zn’+, and partially inhibited the increase in 
binding if added after addition of [‘H]PDBu (table 
1). Thus, the increase in phorbol ester binding in- 
duced by Zn2+ is largely reversible. 
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Fig. 1. (A) Dose dependence of the effect of increasing Zn2+ and 
pyrithione concentrations on [‘H]PDBu binding in B-CLL cells. 
(B) Time course of 65Zn uptake by B-cells and increases in PDBu 
binding after treatment of cells with Zn (50 PM) plus pyrithione 
(5 rM). 
Scatchard analysis showed that the increase in 
binding of t3H]PDBu to B-cells was due to an in- 
crease in the total number of phorbol ester recep- 
tors with little or no change in affinity; similar 
results were obtained with platelets and neutrophil 
polymorphs (fig.2A-C). Fractionation of B-cells 
showed that treatment with Zn2+ caused transloca- 
tion of phorbol receptors from the soluble to the 
particulate (membrane) fraction of cells (table 2), 
but the mechanism for the increase in numbers of 
PDBu receptors was not clear. 
cause an increase in affinity of phorbol receptors 
with little alteration in total numbers [6], a rise in 
cellular total Zn2+ concentration caused a large in- 
crease in the apparent numbers of PDBu receptors 
in B-CLL cells, neutrophils and platelets but only 
small increases in affinity. Similar changes also oc- 
curred in homogenates of B-CLL cells treated 
directly with Zn2+ (not shown). It is of interest hat 
Table 1 
Effect of phenanthroline on the increase in PDBu binding in B- 
cells induced by Zn pyrithione 
[‘H]PDBu binding (cpm) ( f SE) 
The apparent increase in receptor numbers 
observed in intact cells could be due to more rapid 
degradation of PDBu receptors in control prepara- 
tions compared with Zn2+ treated cells during the 
40 min elapsing during the experiment. However, 
there was no loss of [3H]PDBu binding in control 
cells during the course of the experiments. 
Control (no Zn pyrithione) 3977 (*71 ) 
Control + phenanthroline 3260 ( f 121) 
A B 
Zn pyrithione 7407 (* 115) 6996 (+ 105) 
Zn pyrithione + phenan- 
throline 3879 (+ 146) 4702 (&46 ) 
Cells were incubated with either buffer (control) or Zn (50 PM) 
plus pyrithione (20pM) for 30 min before addition of [‘H]PDBu 
(20 nM) and incubation for a further 30 min. Phenanthroline (1 
mM) was added either (A) 10 min after the beginning of incuba- 
In contrast to rises in free cytosolic Ca2+ which tion or (B) 10 min after addition of [‘H]PDBu (n = 4) 
446 
Volume 247, number 2 FEBS LETTERS 
0.04- A 
, 
0.0 0.4 0.8 1.2 
B pmoles/lO~ells 
1.8 
0.03 1 C 
April 1989 
0 50 100 10'50 200 250 
B pmolee/lO platelets 
0.0 0.2 0.4 0.6 
B pmoles/lO cells 
Fig.2. Scatchard plots of [‘H]PDBu binding in the presence or absence of zinc pyrithione (50 PM Zn). (A) B-CLL cells, (B) platelets, 
(C) neutrophil polymorphs. 
Csermely et al. [4] have shown that increases in 
Zn2+ concentration increase the affinity but not the 
number of PDBu receptors in T-cell cytosol and, to 
a lesser extent, T-cell microsomes. 
The physiological significance of the effect of 
Zn2+ on phorbol ester receptors remains unclear; 
furthermore, the free Zn2+ concentrations in either 
the cytosolic or intact cell preparations cannot be 
determined with any certainty [4]. The availability 
of Zn2+ chromophores to estimate intracellular 
free Zn2+ would help to resolve these questions. 
These reservations apart, our data provide 
evidence that increases in cytosolic Zn2+ play a role 
Table 2 
PDBu-binding activity of the soluble and particulate fractions 
of CLL cells after treatment with Zn pyrithione 
[‘HJPDBu binding (cpm) ( f SE) 
Treatment Soluble Particulate 
Control 5659 ( f 62) 4384 ( f 10) 
Zinc pyrithione 3159 (*46) 6346(*84) 
After incubation of B-cells with either buffer (control) or Zn2+ 
(50 /rM) plus pyrithione (20 /cM), cells were sonicated and 
subcellular fractions prepared as described (n = 3) 
in regulating the activity and subcellular distribu- 
tion of PKC, and shed some light on the possible 
significance of the redistribution of Zn2+ which oc- 
curs between whole organs in disease states [7] and 
between cell organelles during cell activation by 
phorbol esters [8]. 
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